Floatz logo

ibi310

DMMR Cancer

Peking Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the DMMR Cancer cohort.

Asset / SponsorPhaseRating
LENVATINIB
Peking University
Phase 2CCC
Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2CCC
Mdna11
Medicenna Therapeutics, Inc.
Phase 1/2CC

Same molecule, other indications

ibi310 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
62 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
acral lentiginous melanomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →